Last updated: 2026-10-12 20:28:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Roivant Sciences Ltd (ROIV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $34,60, with a market capitalisation of $25,60B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15,99 to $42,50. This page covers its latest market performance, valuation, price trends and company information.
$25,60B | |
$34,92 | |
$42,50 | |
$2,52 | |
$35,44 | |
3,96M | |
7,06M | |
-- | |
$42,50 | |
$15,99 | |
-- | |
-- |
Roivant Sciences Ltd (ROIV) is trading at $34,85 in after-hours trading as of 2026-10-12 19:59:54, down 1,68% ($0,59) from the regular-session close of $35,44.
After-hours trading shows how investors are pricing ROIV after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Roivant Sciences Ltd (ROIV) moved from $35,50 to $34,60, representing a decline of 2,54% ($0,90).
The stock traded between $33,12 and $36,79 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 5,32 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 70,2%
ROIV is currently trading at $34,60, placing it 70,2% of the way from its 52-week low of $15,99 to its 52-week high of $42,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 721 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Roivant Sciences Ltd (ROIV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.